NEPH · Nephros Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Nephros reported record Q2 2026 net revenue of $6.0 million, up 36% year-over-year, with core programmatic revenue up 27% and service revenue nearly tripling; however, reported gross margin benefited from a one-time ~$0.6 million IEEPA tariff refund and operating cash flow declined versus the prior-year quarter.
- + Record quarterly net revenue of $6.0 million, up 36% year-over-year.
- + Core programmatic revenue grew approximately 27% year-over-year.
- + Service revenue nearly tripled year-over-year.
- + Net income and adjusted EBITDA roughly quadrupled and roughly tripled, respectively, year-over-year.
- + First-half 2026 revenue grew 21% to $11.2 million with debt-free balance sheet and ~$4.7 million in cash.
- − Q2 operating cash flow declined $313,000 year-over-year to $681,000.
- − Underlying gross margin remains pressured by tariffs, weaker dollar, higher shipping, and lower-margin service/commercial mix.
- − First-half 2026 gross margin slipped to ~63% from ~64% as service/commercial mix offset the tariff refund benefit.
- − Q2 results were inflated by a one-time ~$0.6 million IEEPA tariff refund that boosted gross margin by roughly nine percentage points.
- − Six-month operating cash flow swung to a $990,000 use of cash from $1.3 million provided a year earlier.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEPH
this stock
Nephros Inc
|
$48.54M | -8.4% | +32.7% | 27.9 | 0.4% |
|
ISRG
Intuitive Surgical Inc
|
$130.41B | -34.8% | +20.5% | 42.4 | 2.2% |
|
BDX
Becton Dickinson & Co
|
$48.44B | — | +8.2% | — | 3.9% |
|
MDLN
Medline Inc.
|
$42.77B | -22.5% | +11.5% | — | 3.0% |
|
ALC
Alcon Inc
|
$31.92B | -16.2% | +10.5% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEPH | +6.9% | -4.7% | +53.6% | +4.4% | -8.4% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +8.1% | -2.9% | +35.8% | +4.8% | -20.5% |